Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. / Wenande, Emily; Olesen, Uffe H.; Boesen, Malene R.; Persson, Daniel P.; Lerche, Catharina M.; Sturup, Stefan; Gammelgaard, Bente; Husted, Søren; Anderson, R. Rox; Hædersdal, Merete.

In: Drug Delivery, Vol. 25, No. 1, 2018, p. 1877-1885.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wenande, E, Olesen, UH, Boesen, MR, Persson, DP, Lerche, CM, Sturup, S, Gammelgaard, B, Husted, S, Anderson, RR & Hædersdal, M 2018, 'Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin', Drug Delivery, vol. 25, no. 1, pp. 1877-1885. https://doi.org/10.1080/10717544.2018.1534896

APA

Wenande, E., Olesen, U. H., Boesen, M. R., Persson, D. P., Lerche, C. M., Sturup, S., ... Hædersdal, M. (2018). Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. Drug Delivery, 25(1), 1877-1885. https://doi.org/10.1080/10717544.2018.1534896

Vancouver

Wenande E, Olesen UH, Boesen MR, Persson DP, Lerche CM, Sturup S et al. Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. Drug Delivery. 2018;25(1):1877-1885. https://doi.org/10.1080/10717544.2018.1534896

Author

Wenande, Emily ; Olesen, Uffe H. ; Boesen, Malene R. ; Persson, Daniel P. ; Lerche, Catharina M. ; Sturup, Stefan ; Gammelgaard, Bente ; Husted, Søren ; Anderson, R. Rox ; Hædersdal, Merete. / Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. In: Drug Delivery. 2018 ; Vol. 25, No. 1. pp. 1877-1885.

Bibtex

@article{5859127fce0e4c3a9bc93717e8ccb4e6,
title = "Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin",
abstract = "Systemic chemotherapy with the anticancer agent cisplatin is approved for advanced non-melanoma skin cancer (NMSC), but topical treatment is limited by insufficient cutaneous penetration. We studied the impact of ablative fractional laser (AFL) exposure on topical cisplatin's pharmacokinetics and biodistribution in skin, using microscopic ablation zones reaching the mid- (MAZ-MD; 620 μm depth) and deep dermis (MAZ-DD; 912 μm depth) (λ = 10,600 nm, 196 MAZ/cm 2). Assessed in an in vitro Franz cell model after 0.5-, 4-, 24 h topical exposure (n = 8), cisplatin delivery was greatly accelerated by AFL, shown by quantitative- and imaging-based inductively coupled plasma-mass spectrometry (ICP-MS). After 30 minutes, cisplatin concentrations were 91.5, 90.8 and 37.8 μg/cm 3 in specific 100-, 500, and 1500 μm skin layers respectively, contrasting to 8.08, 3.12, 0.64 μg/cm 3 in non-laser-exposed control skin (p < .001; control vs MAZ-MD). Supported by element bioimaging, the greatest relative increases occurred in the deep skin compartment and at later time points. After 24 h, cisplatin concentrations thus rose to 1829, 1732 and 773 μg/cm 3, representing a 25-, 103- and 447-fold enhancement in the 100, 500, and 1500 μm deep skin layers versus corresponding controls (p < .001; MAZ-MD). A significant difference in cutaneous uptake using MAZ-MD and MAZ-DD was not shown at any time point, though deeper laser channels resulted in increased transdermal cisplatin permeation (p ≤ .015). In conclusion, AFL is a rapid, practical and existing skin treatment that may provide greatly enhanced uptake of topical cisplatin for treatment of superficial and deep skin cancer.",
keywords = "Element bioimaging, fractional ablative CO2 laser, laser-assisted drug delivery, local chemotherapy, non-melanoma skin cancer",
author = "Emily Wenande and Olesen, {Uffe H.} and Boesen, {Malene R.} and Persson, {Daniel P.} and Lerche, {Catharina M.} and Stefan Sturup and Bente Gammelgaard and S{\o}ren Husted and Anderson, {R. Rox} and Merete H{\ae}dersdal",
year = "2018",
doi = "10.1080/10717544.2018.1534896",
language = "English",
volume = "25",
pages = "1877--1885",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin

AU - Wenande, Emily

AU - Olesen, Uffe H.

AU - Boesen, Malene R.

AU - Persson, Daniel P.

AU - Lerche, Catharina M.

AU - Sturup, Stefan

AU - Gammelgaard, Bente

AU - Husted, Søren

AU - Anderson, R. Rox

AU - Hædersdal, Merete

PY - 2018

Y1 - 2018

N2 - Systemic chemotherapy with the anticancer agent cisplatin is approved for advanced non-melanoma skin cancer (NMSC), but topical treatment is limited by insufficient cutaneous penetration. We studied the impact of ablative fractional laser (AFL) exposure on topical cisplatin's pharmacokinetics and biodistribution in skin, using microscopic ablation zones reaching the mid- (MAZ-MD; 620 μm depth) and deep dermis (MAZ-DD; 912 μm depth) (λ = 10,600 nm, 196 MAZ/cm 2). Assessed in an in vitro Franz cell model after 0.5-, 4-, 24 h topical exposure (n = 8), cisplatin delivery was greatly accelerated by AFL, shown by quantitative- and imaging-based inductively coupled plasma-mass spectrometry (ICP-MS). After 30 minutes, cisplatin concentrations were 91.5, 90.8 and 37.8 μg/cm 3 in specific 100-, 500, and 1500 μm skin layers respectively, contrasting to 8.08, 3.12, 0.64 μg/cm 3 in non-laser-exposed control skin (p < .001; control vs MAZ-MD). Supported by element bioimaging, the greatest relative increases occurred in the deep skin compartment and at later time points. After 24 h, cisplatin concentrations thus rose to 1829, 1732 and 773 μg/cm 3, representing a 25-, 103- and 447-fold enhancement in the 100, 500, and 1500 μm deep skin layers versus corresponding controls (p < .001; MAZ-MD). A significant difference in cutaneous uptake using MAZ-MD and MAZ-DD was not shown at any time point, though deeper laser channels resulted in increased transdermal cisplatin permeation (p ≤ .015). In conclusion, AFL is a rapid, practical and existing skin treatment that may provide greatly enhanced uptake of topical cisplatin for treatment of superficial and deep skin cancer.

AB - Systemic chemotherapy with the anticancer agent cisplatin is approved for advanced non-melanoma skin cancer (NMSC), but topical treatment is limited by insufficient cutaneous penetration. We studied the impact of ablative fractional laser (AFL) exposure on topical cisplatin's pharmacokinetics and biodistribution in skin, using microscopic ablation zones reaching the mid- (MAZ-MD; 620 μm depth) and deep dermis (MAZ-DD; 912 μm depth) (λ = 10,600 nm, 196 MAZ/cm 2). Assessed in an in vitro Franz cell model after 0.5-, 4-, 24 h topical exposure (n = 8), cisplatin delivery was greatly accelerated by AFL, shown by quantitative- and imaging-based inductively coupled plasma-mass spectrometry (ICP-MS). After 30 minutes, cisplatin concentrations were 91.5, 90.8 and 37.8 μg/cm 3 in specific 100-, 500, and 1500 μm skin layers respectively, contrasting to 8.08, 3.12, 0.64 μg/cm 3 in non-laser-exposed control skin (p < .001; control vs MAZ-MD). Supported by element bioimaging, the greatest relative increases occurred in the deep skin compartment and at later time points. After 24 h, cisplatin concentrations thus rose to 1829, 1732 and 773 μg/cm 3, representing a 25-, 103- and 447-fold enhancement in the 100, 500, and 1500 μm deep skin layers versus corresponding controls (p < .001; MAZ-MD). A significant difference in cutaneous uptake using MAZ-MD and MAZ-DD was not shown at any time point, though deeper laser channels resulted in increased transdermal cisplatin permeation (p ≤ .015). In conclusion, AFL is a rapid, practical and existing skin treatment that may provide greatly enhanced uptake of topical cisplatin for treatment of superficial and deep skin cancer.

KW - Element bioimaging

KW - fractional ablative CO2 laser

KW - laser-assisted drug delivery

KW - local chemotherapy

KW - non-melanoma skin cancer

U2 - 10.1080/10717544.2018.1534896

DO - 10.1080/10717544.2018.1534896

M3 - Journal article

C2 - 30474430

VL - 25

SP - 1877

EP - 1885

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 1

ER -

ID: 209700701